Cor reports 6-month ESPRIT data

CORR and partner Schering-Plough (SGP) reported follow-up data from their Phase IV ESPRIT study showing a 7.5 percent incidence of death or myocardial infarction (MI) during the six months following intracoronary stent implantation for Integrilin patients versus 11.5 percent of patients receiving placebo (p=0.0015). CORR said this represents a 35 percent reduction in these adverse outcomes. Integrilin is a GPIIb/IIIa platelet inhibitor. ESPRIT was terminated early based on an interim analysis of 1,758 patients that showed a statistically significant reduction in death and myocardial infarction compared to placebo at both 48 hours and 30 days (see BioCentury, Feb. 7, 2000). ...